A view of response and resistance to atomoxetine treatment in children with ADHD: effects of CYP2C19 polymorphisms and BDNF levels.

Esra DemirciElif Funda SenerMelike Kevser GulMuge Gulcihan OnalFatma Dal

Published in: European journal of clinical pharmacology (2022)

To our knowledge, this is the first study to assess the effects of CYP2C19 polymorphisms and BDNF levels together on ATX treatment in children. Further studies with an extensive population are needed to better understand the effects of CYP2C19 polymorphisms on treatment and side effects, as well as the effects of BDNF levels.

Keyphrases

attention deficit hyperactivity disorder
young adults
healthcare
autism spectrum disorder
stress induced
combination therapy
smoking cessation